RNAi Collaborations & Partnerships

Since inception, Arbutus has fostered collaborations and partnerships with leading companies in the RNAi field, including Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals Inc., Merck & Co. Inc., Takeda Pharmaceutical Company, Monsanto, and other undisclosed pharmaceutical and biotechnology companies.

Our Partners


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)

Arbutus has granted a license to Alnylam to use Arbutus' LNP technology to enable RNAi therapeutic products. Arbutus will receive milestone and royalty payments as LNP-enabled products are developed and commercialized. Alnylam currently has three LNP-enabled products in human clinical trials: ALN-TTR02 (patisiran), ALN-VSP, and ALN-PCS02.


 Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA)


In November 2014, Arbutus signed a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc. to license Arbutus' LNP delivery technology for exclusive use in Dicerna's primary hyperoxaluria type 1 (PH1) development program. Dicerna will use Arbutus' third generation LNP technology to deliver DCR-PH1, for the treatment of PH1, a rare inherited liver disorder that often results in kidney failure and for which there are no approved therapies. Arbutus will provide clinical drug supply and regulatory support to advance DCR-PH1.


Arcturus Therapeutics Inc. (Marina Biotech Inc.)

In 2012, Arbutus obtained a worldwide, non-exclusive license to a novel RNAi trigger technology called Unlocked Nucleobase Analog (UNA) from Marina Biotech for the development of RNAi therapeutics. UNAs can be incorporated into RNAi drugs and have the potential to improve them by increasing their stability and reducing off-target effects. Read more about RNA Trigger Technologies here. In October of 2013, Marina assigned its rights and obligations to Arcturus, including Arbutus’ license to the UNAs. 

Spectrum Pharmaceuticals, Inc.

In 2006, Arbutus licensed three liposomal chemotherapy products to Talon Therapeutics: Marqibo® (a liposomal formulation of the chemotherapy drug vincristine); Alocrest (a liposomal formulation of the chemotherapy drug vinorelbine); and, Brakiva (a liposomal formulation of the chemotherapy drug topotecan). In 2013, Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) acquired Talon Therapeutics. Spectrum has launched Marqibo® through its existing hematology sales force. Arbutus receives royalty payments based on Marqibo®’s commercial sales.

 Read more about our Partnered Products here.